Seattle Genetics and Astellas have confirmed that the drug candidate they are co-developing, enfortumab, has been given FDA breakthrough therapy designation.
‘Kankermedicijnen interessant doelwit voor vervalsers’
Kankermedicijnen zijn een interessant doelwit voor geneesmiddelenvervalsers, zo blijkt uit onderzoek van het Rijksinstituut voor Volksgezondheid en Milieu (RIVM). De omvang van het probleem lijkt volgens de onderzoekers...
Pfizer seeks tax breaks in return for planned $456m facility
Pfizer has submitted proposals to officials in Portage, Michigan, for a major expansion of its manufacturing site in the city.
Abbvie pays out over $3m after its testosterone replacement drug leads to heart attack
Abbvie has been ordered to pay over $3 million in damages to a man who asserts that the uise of the company’s testosterone replacement drug AndroGel drove him to a heart attack, a risk which he argues was vastly...
GSK to take control of Consumer Healthcare in £9.2bn buyout
GSK has announced that it plans to purchase Novartis’ 36.5% stake in the joint Consumer Healthcare Business for a sum of £9.2 billion.
GlaxoSmithKline trekt bod op divisie Pfizer in
De verkoop van de consumentengezondheidstak wordt een hoofdpijndossier voor de Amerikaanse farmaceut Pfizer. Branchegenoot GlaxoSmithKline (GSK) heeft zijn bod op de divisie, die onder meer Advil-pijnstillers en Centrum...
Zorgen over toenemende tekorten aan antibiotica
Het College ter Beoordeling van Geneesmiddelen (CBG) is bezorgd over de steeds vaker optredende tekorten aan antibiotica in apotheken. Daarbij gaat het vooral om smalspectrum antibiotica. Dat zijn middelen die specifiek...
Brussel stemt in met overname Monsanto door Bayer
De overname door het Duitse chemiebedrijf Bayer van de Amerikaanse onderneming Monsanto heeft de goedkeuring gekregen van de Europese Commissie. De deal was omstreden wegens de machtspositie die Bayer na de overname zou...
Independent committee report seeks Brexit healthcare clarity
An independent report, entitled Brexit – Medicines, Medical Devices and Substances of Human Origin and written by the Health and Social Care Committee, has called for greater clarity regarding the future for medicine...
NICE turns down Dompe’s eye drops for rare eye condition over price concerns
NICE has announced that it has recommended against the use of Dompe’s recombinant human nerve growth factor eye drop therapy cenegermin on the NHS for the treatment of the rare eye condition neurotrophic keratitis.
Vijf tips voor dieper inzicht in Google Analytics
Uit Google Analytics is bijzonder veel data te halen, maar het is soms lastig de écht nuttige data te zien. De standaardrapporten geven interessante informatie over bezoekers, meest bekeken pagina’s en apparaten. De...
Sun Pharma receives approval for first biologic drug
The beginning of Sun Pharma’s diversification out of generic drugs is here and it’s a drug that MSD, known as Merck in North America, was happy to pass over to the Indian pharma company. The drug is Ilumya and it’s a...
Bayer-Monsanto deal one step closer, after EU nod
The merger between Bayer and agricultural giant, Monsanto, is inching closer to completion after the EU Commission won EU antitrust approval.
GSK withdraws from running for Pfizer Consumer Health
GSK has announced that it has decided to pull out of the race to acquire Pfizer’s Consumer Health business, ending months of speculation.
Lifestyle factors to blame for 38% of cancers
A new study by Cancer Research UK has found that more than 135,500 cases of cancer every year in the UK are due to lifestyle habits, meaning that 37.7% of cancers could potentially be prevented by making simple changes.
J&J’s longest-standing CFO finally steps down
Johnson & Johnson have revealed that its Chief Financial Officer and Executive Vice President, Dominic J. Caruso, will retire from his position in September of this year.
De 5 meest gestelde vragen over AVG/GDPR
Nog twee maanden tot de privacywet AVG/GDPR in werking treedt en nog steeds zijn er veel vragen. Het is in veel artikelen al over marketing gegaan, maar wat is er nu voor iedereen belangrijk? Ik beantwoord de vijf meest...
Celgene bucks trend to strengthen neuroscience pipeline
Celgene has gone against industry movement to back out of the neuroscience area by putting down a potential $2.2 billion to gain options on three drug candidates held by Prothena.



![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)




